Medicago announces two presentations at the 2008 AAPS National Biotechnology Conference



    QUEBEC CITY, June 23 /CNW/ - Medicago Inc. (TSX-V:MDG) (the "Company"),
today announced that it will be presenting an overview of its development of
vaccines generated from plant-made Virus-Like Particles and unique technology
platform at the 2008 American Association of Pharmaceutical Scientists (AAPS)
National Biotechnology Conference, from June 22-25, 2008, at the Metro
Convention Centre in Toronto, Ontario. Dr. Louis Vezina, Medicago's Chief
Scientific Officer will give a presentation on "How to Produce Therapeutic
Vaccines in Plants" in a Plenary Session entitled "Pharmaceutical
Biotechnology - the Next Steps", today at 8:30 am EDT. Ms. Irene Clement,
Acting Vice President Regulatory Affairs will give a presentation on
"Production and Characterization of Plant-based Vaccines and Therapeutic
Antibodies" in a Session entitled "Plant-based Biologicals: Developmental and
Regulatory Aspects" today at 1:00 pm EDT.

    About Medicago

    Medicago is committed to provide highly effective and affordable vaccines
based on proprietary Virus-Like Particle (VLP) and manufacturing technologies.
Medicago is developing VLP vaccines to protect against H5N1 pandemic
influenza, using a transient expression system which produces recombinant
vaccine antigens in non-transgenic plants. This technology has potential to
offer advantages of speed and cost over competitive technologies. It could
deliver a vaccine for testing in about a month after the identification and
reception of genetic sequences from a pandemic strain. This production time
frame has the potential to allow vaccination of the population before the
first wave of a pandemic strikes and to supply large volumes of vaccine
antigens to the world market. Additional information about Medicago is
available at www.medicago.com.

    Forward-Looking Statements

    This press release contains forward-looking statements which reflect
Medicago's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. Medicago disclaims any obligation to
update these forward-looking statements.

    The TSX Venture Exchange assumes no responsibility for the content or
    accuracy of this press release

    %SEDAR: 00023641E




For further information:

For further information: Medicago, Inc., Andy Sheldon, President and
CEO, (418) 658-9393; Investor relations: The Equicom Group Inc., Arianna
Vanin, (514) 844-4680, avanin@equicomgroup.com

Organization Profile

Medicago Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890